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Bullosa Acquisita
Coralie Zumelzu1, Christelle Le Roux-Villet1, Pascale Loiseau2, Marc Busson2,3, Michel Heller4,
Franc¸oise Aucouturier2, Vale´rie Pendaries5, Nicole Lie`vre4, Francis Pascal1,6, Marie-Dominique Brette7,
Serge Doan8, Dominique Charron2, Fre´deric Caux1, Liliane Laroche1, Antoine Petit9 and
Catherine Prost-Squarcioni1,4,9,10
Epidermolysis bullosa acquisita (EBA) is a rare autoimmune bullous disease (AIBD). However, higher EBA
incidence and predisposing genetic factor(s) involving an HLA haplotype have been suspected in some
populations. This retrospective study assessed the overrepresentation of black patients with EBA, its link with
HLA-DRB1*15:03, and their clinical and immunological characteristics. Between 2005 and 2009, 7/13 (54%) EBA
and 6/183 (3%) other-AIBD patients seen consecutively in our department were black (P¼ 106); moreover 7/13
(54%) black patients and 6/183 (3%) white patients had EBA (P¼ 106). In addition, between 1983 and 2005, 12
black patients had EBA. Finally, among the 19 black EBA patients, most of them had very atypical clinical
presentations, 9 were natives of sub-Saharan Africa, 1 from Reunion Island, 7 from the West Indies, and 2 were
of mixed ancestry. HLA-DRB1*15:03 allelic frequencies were 50% for African patients, significantly higher than
the control population (Po103), and 21% for the West Indians (nonsignificant). High EBA frequencies have
already been reported in American blacks significantly associated with the HLA-DR2. In conclusion, black-
skinned patients developing EBA seem to have a genetic predisposition, and EBA should be suspected
systematically for every AIBD seen in this population.
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INTRODUCTION
Epidermolysis bullosa acquisita (EBA) is a rare skin condition
with several different presentations (Woodley et al., 2007;
Lehman et al., 2009). Its ‘‘classical’’ presentation is character-
ized by an acquired, chronic, trauma-induced, subepidermal
blistering disease. Its bullous pemphigoid-like clinical presenta-
tion was described as early as 1982 (Gammon et al., 1982). It
can also have features reminiscent of linear IgA dermatosis,
mucous membrane (MM) pemphigoid, or Brunsting–Perry
pemphigoid. Autoantibody target-antigen characterization in
all these different clinical forms (Woodley et al., 1984) defined
EBA immunologically as a subepidermal autoimmune bullous
disease (AIBD) with autoantibodies to type VII collagen, the
anchoring fibril component (Woodley et al., 1988, 2007).
An EBA-predisposing genetic factor has been suspected
in some populations. EBA may be more common in Asians
(Jin et al., 1993; Lee, 1998; Wong and Chua, 2002) and
an association with the HLA HLA-DRB1*13 was found in
Koreans (Lee et al., 1996). In the USA, the first large series
of EBA patients comprised 18/29 (62%) black patients
of African descent, suggesting a predisposition in African
Americans compared with other origins (Gammon et al.,
1988). Twelve (66%) of those 18 black patients carried the
HLA-DR2 haplotype. Those findings were later disputed,
when another cohort of 24 American patients, considered
similar to the American general population, included 26%
(5/19) African Americans (Chan et al., 1996).
Our clinical experience in France indicated that EBA
predominantly affected blacks of African descent. Therefore,
we undertook this retrospective study to assess this predilec-
tion and, should it exist, to examine whether it could involve
a genetic factor. Study goals were to compare the percentages
ORIGINAL ARTICLE
2386 Journal of Investigative Dermatology (2011), Volume 131 & 2011 The Society for Investigative Dermatology
Received 28 January 2011; revised 3 May 2011; accepted 27 May 2011;
published online 11 August 2011
1Department of Dermatology, Avicenne Hospital, Assistance
Publique–Hoˆpitaux de Paris (AP–HP), UFR Paris 7, Bobigny, France;
2Department of Immunology, Saint-Louis Hospital, AP–HP, Paris, France;
3INSERM UMR940, Saint-Louis Hospital, AP–HP, Paris, France; 4Department
of Histology, UFR Paris 13, Bobigny, France; 5INSERM U563, CHU Purpan,
Toulouse, France; 6Department of Stomatology, Saint-Louis Hospital, AP–HP,
Paris, France; 7Department of Otorhinolaryngology, Saint-Louis Hospital,
AP–HP, Paris, France; 8Department of Ophthalmology, Bichat Hospital,
AP–HP, Paris, France; 9Department of Dermatology, Saint-Louis
Hospital, AP–HP, Paris, France and 10Department of Pathology, Avicenne
Hospital, AP–HP, UFR Paris 13, Bobigny, France; and French Referral Center
for Autoimmune and Toxic Acquired Bullous Dermatoses
Correspondence: Catherine Prost-Squarcioni, Service de Dermatologie,
Hoˆpital Avicenne, 125, Rue de Stalingrad, 93009 Bobigny, France.
E-mail: catherine.prost@avc.aphp.fr
Abbreviations: AIBD, autoimmune bullous disease; EBA, epidermolysis
bullosa acquisita; IF, immunofluorescence; MM, mucous membrane;
PV, pemphigus vulgaris
of black patients with EBA or another AIBD, and of black- or
white-skinned EBA patients; describe in detail the clinical
and immunological EBA characteristics of our 19 black
patients; and look for possible association(s) of certain class II
HLA determinants in black and non-black EBA and other-
AIBD patients.
RESULTS
EBA frequency among black patients
From 1 January 2005 to June 2009, 196 consecutive patients
were seen in our center for the diagnosis of subepidermal
AIBD: 13 (7%) had EBA and 183 (93%) had another AIBD
(Table 1); 13 were black and 183 white. In all, 7 (54%) of the
13 black patients and only 6 (3%) of the 183 white patients
had EBA (P¼ 106). In addition, 7/13 (54%) EBA patients and
only 6/183 (3%) other-AIBD patients were black (P¼106).
Between 1 January 1983 and 1 January 2005, 12 (28%)
black patients among 43 consecutive patients diagnosed with
EBA consulted at our center.
Finally, 19 black EBA patients seen in our referral center
(January 1983–June 2009) were retained for this study. Some
findings for patients 1, 5, 7, 8, 12, 17, and 18 were reported
elsewhere (Wechsler et al., 1982; Karpouzis et al., 1993;
Callot-Mellot et al., 1997; Alexandre et al., 2006).
Clinical characteristics
Among our 19 black patients of African descent with EBA,
11 were females and 8 males (ratio 1.4:1; Table 2). Their age
range was 2–73 (mean, 29; median, 24) years at the time of
EBA diagnosis. Nine were sub-Saharan African natives, one
Table 1. Autoimmune bullous diseases and patient
skin color frequencies
Skin n EBA Other AIBD
n 196 13 183
Black 13 71/13 (54%) 62,3/183 (3%)4
White 183 6/183 (3%)4 177
Abbreviations: AIBD, autoimmune bullous disease; EBA, epidermolysis
bullosa acquisita.
1Origins: West Indies, 4; sub-Saharan Africa, 3.
2Origins: sub-Saharan Africa, 4; Cape Verde, 1; Comoros, 1.
3Diagnoses: cicatricial pemphigoid, 5; IgA bullous pemphigoid, 1.
4P=106 (Fisher’s exact test) for EBA diagnosis for patients with black
versus white skin and EBA diagnosis versus other AIBD for black patients;
odds ratio, 34.4 (95% confidence interval, 7.1–164.6).
Table 2. Demographic and clinical features of our 19 black EBA patients
Patient Sex Age (y)1 Origin Disease duration (months)2 Associated diseases Follow-up available
1 F 27 Benin (SSA) 12 DRESS to sulfasalazine Died
2 F 54 Benin (SSA) 120 Tuberculosis Yes
3 F 27 Benin (SSA) 1 Dapsone syndrome Yes
4 F 41 Togo (SSA) 48 No Yes
5 F 18 Togo (SSA) 0 No No
6 M 19 DR Congo (SSA) 74 Tuberculosis Yes
7 M 2 Togo (SSA) 1 No No
8 F 15 SSA 1 No No
9 M 32 Mali (SSA) 6 Hepatitis C Yes
10 F 20 Cameroon (SSA)–WI 1 Diabetes mellitus, tuberculosis Died
11 M 22 Reunion Island 1 Dapsone syndrome, Crohn’s disease No
12 M 35 Guadeloupe (WI) 264 No No
13 F 73 Martinique (WI) 36 No No
14 F 20 Guadeloupe (WI) 12 Crohn’s disease Yes
15 M 24 Guadeloupe (WI)–Cuba 3 Crohn’s disease Yes
16 M 23 Martinique (WI) 48 No No
17 F 6 Martinique (WI) 1 No No
18 F 58 Guadeloupe (WI) 24 No Died
19 M 33 Guadeloupe (WI)–Brazil 132 No Yes
Abbreviations: DR Congo, Democratic Republic of the Congo; DRESS, drug rash with eosinophilia and systemic symptoms; EBA, epidermolysis bullosa
acquisita; F, female; M, male; SSA, sub-Saharan Africa; WI, West Indies; y, year.
Some of the findings for patients 1 and 5 (Alexandre et al., 2006), 7, 8, and 17 (Callot-Mellot et al., 1997), 12 (Karpouzis et al., 1993), and 18 (Wechsler
et al., 1982) were reported previously.
1At EBA onset.
2Before EBA diagnosis.
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came from Reunion Island, seven were West Indian, and
two were of mixed ancestry. Disease duration before EBA
diagnosis ranged from 1 to 264 (mean, 45; median, 60)
months. EBA was associated with Crohn’s disease, lymph-
node tuberculosis, or chronic hepatitis C in three, three, and
one patients, respectively. No patient satisfied the American
College of Rheumatology criteria for systemic lupus erythe-
matosus. Three patients suffered cutaneous drug reactions
(two dapsone syndromes and one drug rash with eosinophilia
and systemic symptoms with sulfasalazine), soon after
starting treatment. Follow-up of 11 of these 19 patients is
available; three patients died.
All but patient 1 had skin involvement (Figure 1a,
Supplementary Figure S1 online and Supplementary Table
S1 online). Typical trauma-induced skin lesions, milia
formation, and atrophic scars were present in 16 (84%),
11 (58%), and 17 (89%) patients, respectively; 10 (53%)
had spontaneous lesions. Bullous lesions could be small
or large in diameter, flaccid or tense, sometimes in the
same patient, and had a rosette pattern in four. Discerning
erythema in these black patients could be difficult, whereas
old lesion scars were easily seen because they were usually
depigmented. The most frequently involved sites were the
extremities: only three patients did not have lesions on
extensor areas, whereas only four had lesions on flexor areas
(axillae, palms, and/or plantar soles). Six (32%) patients had
nail dystrophy, with complete nail loss for the most severe.
More than half of the 19 patients had head, neck, and/or
trunk lesions: 13 (68%) had head involvement, notably eight
on the face, five (26%) had scalp lesions responsible for
localized or extensive scarring alopecia, and 11 (57%) had
trunk involvement.
Among our 19 black EBA patients, 15 (79%) had one to
four (median two) involved MM site(s) (Figure 1b, Supple-
mentary Figure S2 online and Supplementary Table S2
online), but this involvement was predominant only for
two. Buccal MM (tongue, lip, gingiva, and/or palate) and
nose, pharynx, and/or larynx were affected in 13 (68%) and
12 (63%) patients, respectively, whereas low-grade conjunc-
tivitis (classification grade I, Tauber et al., 1992), genital, and
anal involvements (including one circumferential lesion)
were seen only in 4 (21%), 5 (26%), and 3 (15%) patients,
respectively. In the absence of symptoms suggestive of
esophageal involvement, esophageal and gastric endoscopies
were not performed.
Finally, when first seen in our center, EBA was inflamma-
tory with spontaneous lesions in 10 (53%) patients, including
the 3 children, whereas only 6 (32%) patients had classical
trauma-induced lesions without spontaneous lesions. Patients
1 and 6, and 12, respectively, had MM pemphigoid-like and
Brunsting–Perry pemphigoid-like presentations. Comparing
patients with inflammatory EBA versus those with another
clinical presentation showed that the four patients with
rosette-pattern lesions, but only two of the four patients with
lesions on extremity flexor areas, indeed had inflammatory
disease. Inflammatory EBA in our patients of African descent
was significantly associated with head (face), trunk, and
buccal MM (buccal mucosa) lesions. Comparisons of sub-
Saharan African and West Indian patients showed no
significant differences in their clinical presentations (Supple-
mentary Table S3 online).
Immunological findings
Direct immunofluorescence (IF) on biopsy specimens labeled
linear immune deposits on the basement-membrane zone,
and direct immunoelectron microscopy detected immune
deposits within the anchoring fibril zone in all patients
(Table 3 and Supplementary Figure S3 online). IgG, C3, and/
or IgA were present in 19 (100%), 13 (68%), and 3 (16%)
patients, respectively. Indirect IF on rat or monkey esophagus
labeled the basement-membrane zone, indirect IF on salt-
split skin yielded dermal labeling, and ELISA for type VII
collagen was positive for 6 (32%), 7 (38%), and 13 (72%) of
19, 18, and 18 sera tested, respectively. Six patients had
antinuclear antibodies titers 41/80.
Comparing inflammatory EBA to other forms, the percent-
ages of direct IF-detected C3 deposits, indirect IF positivity on
salt-split skin, and ELISA positivity for type VII collagen did
not differ significantly, nor did immunological characteristics
of sub-Saharan African and West Indian patients (Supple-
mentary Table S3 online).
a
b
Figure 1. Epidermolysis bullosa acquisita lesions. (a) Inflammatory
spontaneous lesions involving the face with depigmented scars. (b) Mucous
membrane involvement: bullous lesions of the lower lip.
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HLA-DRB1* alleles were typed for 16/19 patients (Table 3),
with 12 (75%) carrying HLA-DRB1*15; 14 of the 16 were
also HLA-DQB1* typed, with 10 bearing HLA-DQB1*06:02,
all of whom had HLA-DRB1*15 typing. HLA-DRB1*15
subtyping detected HLA-DRB1*15:03 in 10 (83%) and
HLA-DRB1*15:01 in 2 (17%) of them. HLA-DRB1*15:03
allelic frequency in the seven West Indians was 21% (3/14).
Comparing all our West Indians with Martinicans (8%, posted
on the internet: Middleton et al., 2003; Solberg et al.,
2008) found no significant differences (Table 4). The HLA-
DRB1*15:03 allelic frequency among our nine non–West
Indian black EBA patients was 50% (9/18), significantly
higher than all the sub-Saharan countries except Cameroon,
and the difference was highly significant when compared
with Senegalese, Malian, and Ethiopian frequencies.
DISCUSSION
EBA is a rare subepidermal AIBD, with estimated annual
incidence per million inhabitants of 0.26 in France
(Bernard et al., 1995), 0.22 and 0.5 in two German regions
(Zillikens et al., 1995; Bertram et al., 2009), 0.23 in Koweit
(Nanda et al., 2004), and 0.5 in Singapore (Wong and
Chua, 2002). For consecutive subepidermal AIBD patients’
sera tested on salt-split skin, EBA serum rates differed widely
from one country to another: 1.3% in the UK (Logan et al.,
1987), 5% in Uganda (Mulyowa et al., 2006) and New York
City (USA; Zhu et al., 1990), 8% in China (Jin et al., 1993),
but 20% in North Carolina (USA; Gammon et al., 1984)
and 30% in Korea (Lee, 1998). Among our 196 consecutive
subepidermal AIBD patients investigated by direct immuno-
electron microscopy (January 2005–June 2009), 7% had EBA.
However, after separating black and white patients, that
rate rose to 54% for blacks of African descent and declined
to 3% for whites. This difference was highly significant and
agrees with North Carolina data on the first large series
of EBA patients including 18/29 (62%) with black skin
(Gammon et al., 1988).
Our referral center diagnosed 19 black EBA patients
(January 1983–June 2009): 8 West Indians and 11 natives of
sub-Saharan Africa or Reunion Island. In all, 6 (60%) of the
10 sub-Saharan Africans came from Togo or Benin. These
percentages are significantly higher than those of Togolese
(1.98%) and Beninese (1.58%) residing in the Paris metro-
politan area in 2008 (data obtained from French Ministry of
Foreign Affairs; Supplementary Table S4 online), and higher
than those of Togolese (5.5%) and Beninese (2.75%) who
Table 3. Immunological data for 19 black EBA patients
HLA1 DIF IIF
Patient Origin DRB1 DQB1 IEM IgG C3 IgA Esophagus2 SSS3 ANA ELISA4
1 Benin (SSA) 1503/08 0602 or 11/0301 or 09 AFz+ +   1/100 — 0 27
2 Benin (SSA) 1503/13 0602/0603 AFz+ + +  0 — 1/1,600 54.5
3 Benin (SSA) 1503/ 0602/ AFz+ + +  1/500 F+++ 1/600 25
4 Togo (SSA) 1503/0302 or 08 0602/0402 AFz+ +   0 — 0 22.65
5 Togo (SSA) 1503/08 0602 or 11/0301 or 09 AFz+ + +  0 — 0 99.25
6 DR Congo (SSA) 1503/ 0602 /0202 AFz+ ++ +  1/100 — 0 26.7
7 Togo (SSA) 1501/1303 0602/0301 AFz+ + +  1/200 F++ 0 30
8 SSA 1501/1304 ND AFz+ + +  1/200 — 0 5
9 Mali (SSA) ND ND AFz+ +   0 — 0 6.3
10 Cameroon (SSA)–WI ND ND AFz+ +   0 F++ 0 ND
11 Reunion Island 1503/11 0501/0303 AFz+ + + + 0 — 1/500 51.2
12 Guadeloupe (WI) 1503/08 0602/0301 AFz+ + + + 0 — 0 10.8
13 Martinique (WI) 1503/09 0602/0202 AFz+ +  + 0 F++ 1/600 34
14 Guadeloupe (WI) 11/14 0502/0503 AFz+ + +  0 F+ 0 24.1
15 Guadeloupe (WI)–Cuba 13/13 0202/0501 AFz+ + +  0 — 1/600 2.2
16 Martinique (WI) 12/08 0501/0402 AFz+ + +  0 — 0 11.2
17 Martinique (WI) 1101/04 or 03 ND AFz+ + +  0 — 0 53
18 Guadeloupe (WI) ND ND AFz+ + +  janv-00 F+++ 0 95
19 Guadeloupe (WI)–Brazil 1503/07 0602/0202 AFz+ +   0 F+ 1/400 25.86
Abbreviations: AFz, anchoring fibrils zone; ANA, antinuclear antibodies; DIF, direct immunofluorescence; DR Congo, Democratic Republic of the Congo;
EBA, epidermolysis bullosa acquisita; F, floor; IEM, immunoelectron microscopy; IIF, indirect immunofluorescence; ND, not done; SSA, sub-Saharan Africa;
SSS, salt-split skin; WI, West Indies.
1Bold values are the HLA-DRB1*15:03 allele significantly associated with EBA and the known DRB1*15–DQB1*06:02 linkage disequilibrium.
2Rat and/or monkey.
3Semi-quantitative evaluation.
4Positivity to type VII collagen 417 arbitrary units.
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consulted in 14 dermatology departments in this region
during the spring of 2004 (unpublished data from Arsouze
et al., 2008). Those data support that our findings do not
represent a bias linked to greater Togolese and Beninese
representation in France.
We provided detailed clinical and immunological charac-
teristics of our 19 consecutive black EBA patients. Numerous
reviews concerned EBA (Gammon, 1988; Woodley, 1988;
Woodley et al., 1988, 2007) but, to our knowledge, detailed
information was reported only for two EBA series (Briggaman
et al., 1985; Delgado et al., 2010) and only three papers
provided data on black EBA patients (Gammon et al., 1988;
Chan et al., 1996; Howard and Brunner, 2009). Comparing
our observations with the literature, the most striking EBA
particularities in black patients of African descent are their
young age, the high frequencies of inflammatory forms, MM
involvement, severely compromising esthetic impact and
adverse cutaneous drug reactions to EBA therapeutic agents,
a rare association with Crohn’s disease, and poor prognoses
(3 deaths among the 11 patients with follow-up). Notably, our
patients were younger (mean age, 29; median, 24 years) than
those previously reported by Briggaman et al. (1985; mean
age, 54; median, 51 years), Gammon et al. (1988; mean age,
47; median 54 years), and Chan et al. (1996; mean age,
53 years).
All previously described clinical presentations were
observed: 52% of our 19 patients had inflammatory disease,
whereas the classical, MM pemphigoid-like, and Brunsting–-
Perry pemphigoid-like forms were seen in 32, 11, and
5%, respectively. The reported frequencies of inflammatory
clinical presentations varied widely: Briggaman et al. (1985)
from North Carolina reported 5/12 (40%) inflammatory bullous
pemphigoid-like forms in patients of unknown ethnicity,
whereas Woodley et al. (2003) described inflammatory forms
in only 25% of EBA patients. The inflammatory forms of our
patients, characterized by spontaneous bullous lesions rather
than erythema, which are sometimes difficult to discern in
black skin, were significantly associated with facial and/or
trunk and buccal MM lesions. In addition, rosette-pattern
bullous lesions suggestive of a linear IgA dermatosis were
seen in half of them. In contrast, no patient’s EBA mimicked
bullous pemphigoid with predominant lesions on flexor areas
of the extremities.
Fifteen (79%) of our patients had MM involvement: the
most frequently involved site (68%) was mouth with tongue
and labial lesions (unusual in other AIBD, personal observa-
tions) and nose, pharynx, and/or larynx localizations, especial-
ly the nose, followed closely (63%). These nose, pharynx, and/
or larynx lesions could be asymptomatic or symptomatic
(nasal crusting, nasal airway obstruction, epistaxis, pharyn-
galgia, dyspnea and/or dysphonia). The laryngeal lesions
of patient 1 caused her death. In contrast, conjunctival
involvement was present in only 26% of our patients, all of
whom had conjunctivitis without severe fibrosis at EBA
diagnosis. MM involvement frequency herein was higher
than that for all previously reported patients, except in the
prospective study by Alexandre et al. (2006), who reported
67%: among 12 patients in the Briggaman et al. (1985) study,
only 1 (8%) had MM involvement and in the Woodley et al.
study, 30–50% of the patients had buccal MM involvement
(Woodley, 1988; Woodley et al., 1988). All cutaneous lesions
healed in our patients, leaving atrophic and hypo-
pigmented scars, which severely compromised their esthetic
outcomes because they were located on exposed areas
(face, scalp, hands) and were very unsightly. Crohn’s disease
was concomitant in only three (16%) of our patients versus
Table 4. Statistical analysis of HLA-DRB1*15:03 allele frequencies in our West Indian and non–West Indian EBA
patients versus controls in other nations1
Allele frequencies
Comparison
Kilometers
from Yaounde´2 Our patients Other nations1 P Pc OR (95% CI)
7 West Indian patients versus Martinique — 0.21 0.08 0.12 0.12 —
9 Non–West Indian patients versus
Cameroon 0 0.5 0.29 0.09 0.72 —
CAR Aka Pygmies 778 0.5 0.12 0.001 0.008 7.32 (2.12–24.59)
Benin–Togo B1,000 0.5 ND ND ND ND
Rwanda 2,158 0.5 0.17 0.003 0.024 4.89 (1.55–15.31)
Mali (Doggon) 2,360 0.5 0.04 0.0000004 0.0000032 26.6 (6.93–98.7)
Ethiopia (Oromo) 3,060 0.5 0.09 0.0001 0.0008 10.07 (2.79–35.22)
Zimbabwe (Shona) 3,212 0.5 0.15 0.002 0.016 5.54 (1.74–17.47)
Senegal (Dakar) 3,391 0.5 0.02 0.00000006 0.00000048 43.8 (9.64–203.29)
Abbreviations: CAR, Central African Republic; CI, confidence interval; EBA, epidermolysis bullosa acquisita; Pc, P-value corrected by the number of tests
done; OR, odds ratio.
Bold values are highly significant corrected P-values.
1Obtained from the following two websites: http://www.pypop.org/popdata and http://www.allelefrequencies.net.
2Capital of Cameroon.
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25% reported by Chen et al. (2002). The EBA associations
with lymph-node tuberculosis in three patients and chronic
hepatitis C in one patient were probably fortuitous. Despite
high antinuclear antibodies titers in six black-skinned EBA
patients, none met American College of Rheumatology criteria
for systemic lupus erythematosus, similar to our black patients
with another AIBD. Three patients developed cutaneous
drug reactions to sulfasalazine or dapsone, limiting their
subsequent therapeutic options. Last, three patients died,
soon after disease onset, of laryngeal involvement, extensive
cutaneous lesions and resistant tuberculosis, or extensive
cutaneous lesions.
Because HLA genes are highly polymorphic, this high
diversity has led to their use for population studies (Solberg
et al., 2008). Specific HLA polymorphisms have also been
associated with susceptibility to various autoimmune dis-
eases, thereby predisposing certain populations to certain
autoimmune diseases. The HLA alleles associated with these
latter belong to the class II family of molecules, including DR,
DQ, and DP. They encode transmembrane glycoproteins that
present self-peptides to specific T cells. Pemphigus vulgaris
(PV) is a striking example of the HLA role in autoimmune
diseases: susceptibility to PV is linked to HLA-DRB1*04:02
and, among Ashkenazi Jews,490% of PV patients carry that
haplotype, which is rare in the general population. In contrast, in
other ethnic groups (non-Ashkenazi Jews, Caucasians, Japanese),
PV susceptibility is linked to the rare HLA-DQB1*05:03 allele
(reviewed in Wucherpfennig et al., 1995).
A literature search found three studies investigating the
HLA groups implicated in EBA. Gammon et al. (1988) found
a significant association between HLA-DR2 (corresponding
to HLA-DRB1*15) and EBA in black Americans of African
descent: 66.7% of EBA patients versus 28.5% of the control
black-skinned population. At that time, subgroups were not
analyzed and no further information has been reported.
Welsh and Woodley (1992) described a possible HLA-
DR5–EBA association in white patients from South Carolina:
56% of their white EBA patients versus 18% of their white
controls. A Korean study found a significant HLA-DRB1*13–
EBA association (Lee et al., 1996): 6/12 (50%) EBA patients
versus 22.3% of the controls.
Databases showed HLA-DRB1*15:03 to have a high
frequency in Africa, with a specific geographic distribution
characterized by a ‘‘hot spot’’ (highest frequency) located in
Yaounde´, Cameroon. Leaving that epicenter, the frequencies
decreased concentrically (Figure 2; Solberg et al., 2008).
The HLA-DRB1*15:03 commonality in black Americans
(26.3%; Lee et al., 1999), Colombians (18%, 15%, and
13%, respectively, for Providencia, Cauca, and Choco
groups; Trachtenberg et al., 1996), and Jamaicans (10.2%;
Heward et al., 2002) suggests that HLA-DRB1*15:03 could
be an ethnic marker of African origin. Our analyses showed
that HLA-DRB1*15:03 allele was significantly more frequent
among our black-skinned EBA patients from sub-Saharan
countries than the control population, comprised of individ-
uals from sub-Saharan countries where this incidence
had been determined (Middleton et al., 2003; Solberg
et al., 2008): Central African Republic (Aka Pygmies), Mali,
Ethiopia, Zimbabwe, and Senegal, with the exception of
Cameroon. Unfortunately, no data on HLA-DRB1*15:03 rates
are available for Benin and Togo. However, a low frequency
(0.0942039) of this HLA allele would be expected in these
countries based on the worldwide HLA-DRB1*15:03 dis-
tribution (Figure 2), knowing that distances from Yaounde to
the Togo and Benin capitals are, respectively, 1051 km and
1164 km. Notably, five of our six EBA patients originating
from Benin or Togo carried HLA-DRB1*15:03, suggesting
that an association between this HLA subgroup and black
EBA patients from those countries might also exist. In contrast,
HLA-DRB1*15:03 frequency in our black West Indian EBA
patients did not differ significantly from that observed in
the general Martinican population, probably because of
the small number of patients. It should be noted that none
of our black patients with an AIBD other than EBA carried
HLA-DRB1*15:03. Last, HLA-DQB1*06:02 was found in
10 patients, all of whom had HLA-DRB1*15 typing, in accor-
dance with the well-known DR–DQ linkage disequilibrium,
DRB1*15–DQB1*06:02.
Two hypotheses might explain this significant HLA-
DRB1*15:03–EBA association. First, HLA-DRB1*15:03 is
merely an EBA marker because it is in disequilibrium linkage
with an EBA susceptibility gene close to the HLA-DRB1
locus. Second, HLA-DRB1*15:03 really participates in EBA
pathogenesis, in analogy with different major histocompat-
ibility complex haplotypes having been shown to have
pivotal roles in several autoimmune diseases, notably PV.
This hypothesis was raised in the Gammon et al. (1988)
study, first publication on African Americans, and was then
dropped. Ludwig et al. (2011) provided further support, based
on their demonstration of a linkage between the murine
major histocompatibility complex H2s allele and EBA
development in an active-induction mouse model of EBA.
Another supportive argument would be a high EBA frequency
in the countries where HLA-DRB1*15:03 is more common.
To our knowledge, no paper has reported on different AIBD
incidences in Central and Western Africa.
Therefore, major histocompatibility complex genes alone are
apparently not the only EBA susceptibility genes in experimental
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Figure 2. Worldwide distribution frequencies of the HLA-DRB1*15:03 allele.
Distribution was inferred from population samples indicated by white dots.
The red, orange, yellow, green, and blue regions correspond to interpolated
allele frequencies. Gray zones are too far from a sampled population to
yield meaningful frequency estimations. Image reproduced with permission
from Solberg et al. (2008) available at http://www.pypop.org/popdata.
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EBA (Ludwig et al., 2011), as in other autoimmune diseases.
Indeed, it is well established that polymorphisms of genes
encoding autoantigens contribute to autoimmune-trait sus-
ceptibility in myasthenia gravis (Garchon et al., 1994),
insulin-dependent diabetes mellitus (Bennett et al., 1995),
and pemphigus foliaceus (Martel et al., 2001). Notably, the
single-nucleotide polymorphism database of the National
Center for Biotechnology Information contains 282 experi-
mentally validated type VII collagen-a1 (COL7A1) human-
sequence variants but, to our knowledge, they were not
investigated in specific population groups. COL7A1 gene
polymorphisms in our black-skinned EBA patients and a
cohort of ethnically matched controls should now be studied
to test the hypothesis of variations within this locus that might
enhance T-cell recognition of type VII collagen presented
by HLA-DRB1*15:03, thereby conferring additional suscep-
tibility to EBA. Obviously, the best way to determine all the
non-major histocompatibility complex EBA susceptibility
genes would be a genome-wide association scan, as has been
done for insulin-dependent diabetes mellitus, systemic lupus
erythematosus, Crohn’s disease, and rheumatoid arthritis
(Hill et al., 2008).
In conclusion, EBA was significantly more frequent in
black patients in France than in others and was signifi-
cantly more frequent than other subepithelial AIBD in black
patients. A significant HLA-DRB1*15:03 association with
black patients from sub-Saharan Africa suggested a genetic
predisposition to EBA in black patients of African origin.
Moreover, their EBA was characterized by the young age at
its onset, its poor prognosis, a low rate of concomitant Crohn’s
disease, and its frequently misleading clinical presentation,
particularly spontaneous lesions on the head and trunk.
Consequently, when a black patient develops subepidermal
AIBD, a diagnosis of EBA should systematically be suspected
to quickly initiate appropriate and effective treatment.
PATIENTS AND METHODS
Patients
The files of all consecutive AIBD patients seen in our referral center
(January 2005–June 2009) were reviewed. AIBD was defined as
an MM or skin bullous disease with linear IgG, IgA, and/or C3
deposits along the basement-membrane zone detected by direct
IF examination of skin and/or MM biopsies. EBA was diagnosed
when immunoelectron microscopy examination of MM and/or
skin samples showed immune deposits within the anchoring fibril
zone under the lamina densa. The files of all EBA patients seen in
our institution between 1 January 1983 and 1 January 2005 were
similarly reviewed.
‘‘Black-skinned’’ patients from both periods were defined as
having dark skin phototype (V–VI) and originating from sub-Saharan
Africa or the West Indies; skin phototype and country of origin were
always noted on the standardized form used for bullous diseases in
our center.
During the first consultation in our center, along with the usual
demographic information, clinical findings were systematically
recorded, particularly lesion pattern and distribution in different
MM and skin sites, and American College of Rheumatology criteria
for systemic lupus erythematosus (Tan et al., 1982; Hochberg, 1997).
Immunological studies
Direct IF and indirect IF on rat and/or monkey esophagus and
salt-split skin, as well as antinuclear antibodies, were routinely
processed, and direct immunoelectron microscopy and ELISA
for type VII collagen were performed as previously described
(Prost et al., 1987; Pendaries et al., 2010).
HLA-DRB1 and -DQB1 were phenotyped in genomic DNA
extracted from peripheral blood leukocytes. PCR sequence-specific
oligonucleotides and reverse dot-blot kits (InnoLipa DRB and
DQB kits, respectively, Innogenetics, Zwijndrecht, Belgium)
were used for medium-resolution typing, and completed with a
PCR sequence-specific primer and PCR–restriction fragment
length polymorphism techniques for DRB1*15 allelic determination
(Genovision, West Chester, PA).
All patient samples were collected with written informed consent
and adherence to the Declaration of Helsinki Principles. All experiments
were approved by the CPP (Comite´ de Protection des Personnes)—
Toulouse I medical ethical committee.
Statistical analyses
Percentages of black patients with EBA versus another
AIBD and black versus white EBA patients were compared with
Fisher’s exact test. Patients with inflammatory and other EBA forms
were compared for their frequencies of several clinical and
immunological characteristics using a w2 test (or Fisher’s exact test,
when appropriate) for categorical variables and Mann–Whitney test
for continuous variables. All tests were two-sided and Po0.05 was
considered significant.
HLA-typing associations were assessed with w2 test and world-
wide frequency distributions available from databases (http://www.
allelefrequencies.net and http://www.pypop.org/popdata) for sub-
Saharan African populations (Cameroon, Central African Republic (Aka
Pygmies), Mali (Doggon), Ethiopia (Oromo), Rwandan, Zimbabwe
(Shona), Senegal (Dakar)) and the West Indies.
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